Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WILLIAM H JOHNSTON JR.

Allopathic & Osteopathic Physicians Pediatrics

NPI
1740385764
CMS profile
33341
Location
BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,472.90

4 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $955.05 3
Food and Beverage $517.85 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,472.90 4

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WILLIAM H JOHNSTON JR.

NPI 1740385764 · CMS profile ID 33341

Allopathic & Osteopathic Physicians / Pediatrics

BIRMINGHAM, AL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740385764?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740385764?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740385764?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
WILLIAM H JOHNSTON JR., NPI 1740385764, CMS profile ID 33341, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–4 of 4 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1740385764?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

4 matching records · $1,472.90 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 4 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–4 of 4.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ModernaTX, Inc. $517.8508/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981215 CMS
ModernaTX, Inc. $573.4008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981219 CMS
ModernaTX, Inc. $206.7208/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981223 CMS
ModernaTX, Inc. $174.9308/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056981231 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114.86 8
PY2023 $1,472.90 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $209,872.28 58
PY2024 Recipient $5,150.00 1
PY2024 Principal investigator $338,079.53 66
PY2023 Principal investigator $405,526.56 39
PY2022 Recipient $935.00 2
PY2022 Principal investigator $477,955.66 57
PY2021 Recipient $1,025.77 2
PY2021 Principal investigator $105,200.85 39
PY2020 Recipient $446.71 1
PY2020 Principal investigator $92,105.43 57
PY2019 Principal investigator $346,813.45 159

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

159 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Allergan Inc. $2,164.28 12/31/2019 Non-covered Recipient Entity
CENTRAL RESEARCH ASSOCIATES INC
Clinical Trial LIN-MD-64 Ped FC Trial 6-17 Ph3 No dispute reported 06/30/2026 670121324
Principal investigator 1 AstraZeneca Pharmaceuticals LP $221.43 12/31/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics Llc
MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial No dispute reported 06/30/2026 684973433
Principal investigator 1 Allergan Inc. $700.00 11/21/2019 Non-covered Recipient Entity
COPERNICUS GROUP INCORPORATED DBA COPERNICUS GROUP
Chronic Idiopathic Constipation CIC,Irritable Bowel Syndrome with Constipation IBS-C No dispute reported 06/30/2026 670103109
Principal investigator 1 PFIZER INC. $148.44 11/06/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 671677687
Principal investigator 1 PFIZER INC. $1,757.52 09/18/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 671669975
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 09/13/2019 Non-covered Recipient Entity
BIRMINGHAM PEDIATRIC RESEARCH
A Phase II, Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13 in Healthy Infants No dispute reported 06/30/2026 691418701
Principal investigator 1 SANOFI PASTEUR INC. $14,500.00 08/06/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691622543
Principal investigator 1 Merck Sharp & Dohme Corporation $42.51 07/24/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691410681
Principal investigator 1 Merck Sharp & Dohme Corporation $48.33 07/24/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691410689
Principal investigator 1 Merck Sharp & Dohme Corporation $77.31 07/24/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691411251
Principal investigator 1 Merck Sharp & Dohme Corporation $77.67 07/24/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691411255
Principal investigator 1 PFIZER INC. $148.44 07/24/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS LLC
A PHASE 3 RANDOMIZED ACTIVECONTROLLED OBSERVERBLINDED STUDY TO ASSESS THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF BIVALENT RLP2086 WHEN ADMINISTERED AS A 2DOSE REGIMEN AND A FIRSTINHUMAN STUDY TO DESCRIBE THE IMMUNOGENICITY SAFETY AND TOLERABILITY OF A BIVALENT RLP2086CONTAINING PENTAVALENT VACCINE MENABCWY IN HEALTHY SUBJECTS10 TO 26 YEARS OF AGE No dispute reported 06/30/2026 671654515
Principal investigator 1 Merck Sharp & Dohme Corporation $0.38 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691408937
Principal investigator 1 Merck Sharp & Dohme Corporation $1.40 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409419
Principal investigator 1 Merck Sharp & Dohme Corporation $1.40 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409423
Principal investigator 1 Merck Sharp & Dohme Corporation $105.48 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409435
Principal investigator 1 Merck Sharp & Dohme Corporation $55.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409895
Principal investigator 1 Merck Sharp & Dohme Corporation $55.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409899
Principal investigator 1 Merck Sharp & Dohme Corporation $6.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409903
Principal investigator 1 Merck Sharp & Dohme Corporation $6.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409907
Principal investigator 1 Merck Sharp & Dohme Corporation $605.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409911
Principal investigator 1 Merck Sharp & Dohme Corporation $8.80 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409917
Principal investigator 1 Merck Sharp & Dohme Corporation $9.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409919
Principal investigator 1 Merck Sharp & Dohme Corporation $92.76 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409921
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409925
Principal investigator 1 Merck Sharp & Dohme Corporation $247.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409935
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409939
Principal investigator 1 Merck Sharp & Dohme Corporation $34.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691409951
Principal investigator 1 Merck Sharp & Dohme Corporation $528.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411353
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411359
Principal investigator 1 Merck Sharp & Dohme Corporation $67.20 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411363
Principal investigator 1 Merck Sharp & Dohme Corporation $67.20 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411365
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411369
Principal investigator 1 Merck Sharp & Dohme Corporation $7.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411371
Principal investigator 1 Merck Sharp & Dohme Corporation $20.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411381
Principal investigator 1 Merck Sharp & Dohme Corporation $242.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411385
Principal investigator 1 Merck Sharp & Dohme Corporation $242.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411389
Principal investigator 1 Merck Sharp & Dohme Corporation $14.08 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411583
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411589
Principal investigator 1 Merck Sharp & Dohme Corporation $168.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411593
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411597
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691411601
Principal investigator 1 Merck Sharp & Dohme Corporation $19.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412051
Principal investigator 1 Merck Sharp & Dohme Corporation $198.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412055
Principal investigator 1 Merck Sharp & Dohme Corporation $2.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412059
Principal investigator 1 Merck Sharp & Dohme Corporation $2.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412127
Principal investigator 1 Merck Sharp & Dohme Corporation $2.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412129
Principal investigator 1 Merck Sharp & Dohme Corporation $2.75 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412133
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412237
Principal investigator 1 Merck Sharp & Dohme Corporation $35.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412242
Principal investigator 1 Merck Sharp & Dohme Corporation $47.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412247
Principal investigator 1 Merck Sharp & Dohme Corporation $49.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412317
Principal investigator 1 Merck Sharp & Dohme Corporation $5.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412321
Principal investigator 1 Merck Sharp & Dohme Corporation $528.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412325
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412669
Principal investigator 1 Merck Sharp & Dohme Corporation $13.60 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412671
Principal investigator 1 Merck Sharp & Dohme Corporation $1,325.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412675
Principal investigator 1 Merck Sharp & Dohme Corporation $137.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691412677
Principal investigator 1 Merck Sharp & Dohme Corporation $48.40 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691418787
Principal investigator 1 Merck Sharp & Dohme Corporation $68.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419229
Principal investigator 1 Merck Sharp & Dohme Corporation $6.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691419299
Principal investigator 1 Merck Sharp & Dohme Corporation $0.68 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691420011
Principal investigator 1 Merck Sharp & Dohme Corporation $1,320.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691420017
Principal investigator 1 Merck Sharp & Dohme Corporation $16.50 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691420575
Principal investigator 1 Merck Sharp & Dohme Corporation $2.00 07/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691420581
Principal investigator 1 SANOFI PASTEUR INC. $6,065.00 07/09/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691619027
Principal investigator 1 SANOFI PASTEUR INC. $13,400.00 07/09/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691623499
Principal investigator 1 SANOFI PASTEUR INC. $8,500.00 07/09/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691624721
Principal investigator 1 Merck Sharp & Dohme Corporation $12,500.00 06/28/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691345657
Principal investigator 1 Merck Sharp & Dohme Corporation $11,550.87 06/14/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691344899
Principal investigator 1 Merck Sharp & Dohme Corporation $1.20 06/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364320
Principal investigator 1 Merck Sharp & Dohme Corporation $12.10 06/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364323
Principal investigator 1 Merck Sharp & Dohme Corporation $4.04 06/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364401
Principal investigator 1 Merck Sharp & Dohme Corporation $4.84 06/10/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364409
Principal investigator 1 SANOFI PASTEUR INC. $4,680.00 06/06/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618827
Principal investigator 1 Merck Sharp & Dohme Corporation $80.75 06/04/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691409995
Principal investigator 1 Merck Sharp & Dohme Corporation $552.85 06/04/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691410771
Principal investigator 1 Merck Sharp & Dohme Corporation $584.04 06/04/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691411243
Principal investigator 1 Merck Sharp & Dohme Corporation $61.60 06/04/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691411247
Principal investigator 1 SANOFI PASTEUR INC. $34,490.00 06/04/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618145
Principal investigator 1 SANOFI PASTEUR INC. $6,500.00 06/04/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691620611
Principal investigator 1 Merck Sharp & Dohme Corporation $16,660.00 05/23/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691345137
Principal investigator 1 Merck Sharp & Dohme Corporation $2,900.00 05/23/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691345145
Principal investigator 1 Merck Sharp & Dohme Corporation $7,727.61 05/20/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691312291
Principal investigator 1 Merck Sharp & Dohme Corporation $14.20 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363683
Principal investigator 1 Merck Sharp & Dohme Corporation $65.89 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363687
Principal investigator 1 Merck Sharp & Dohme Corporation $1,584.00 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363763
Principal investigator 1 Merck Sharp & Dohme Corporation $165.00 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363769
Principal investigator 1 Merck Sharp & Dohme Corporation $19.80 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363773
Principal investigator 1 Merck Sharp & Dohme Corporation $201.60 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363843
Principal investigator 1 Merck Sharp & Dohme Corporation $22.80 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363845
Principal investigator 1 Merck Sharp & Dohme Corporation $247.50 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363849
Principal investigator 1 Merck Sharp & Dohme Corporation $7.80 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364327
Principal investigator 1 Merck Sharp & Dohme Corporation $3.50 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364331
Principal investigator 1 Merck Sharp & Dohme Corporation $30.92 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364335
Principal investigator 1 Merck Sharp & Dohme Corporation $35.16 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364339
Principal investigator 1 Merck Sharp & Dohme Corporation $4.20 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364405
Principal investigator 1 Merck Sharp & Dohme Corporation $423.50 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364413
Principal investigator 1 Merck Sharp & Dohme Corporation $57.00 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691364441
Principal investigator 1 Merck Sharp & Dohme Corporation $40.80 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372729
Principal investigator 1 Merck Sharp & Dohme Corporation $6.80 05/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372795
Principal investigator 1 Merck Sharp & Dohme Corporation $1,800.00 05/07/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691345141
Principal investigator 1 SANOFI PASTEUR INC. $6,790.00 05/07/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618305
Principal investigator 1 SANOFI PASTEUR INC. $7,000.00 05/07/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618975
Principal investigator 1 SANOFI PASTEUR INC. $11,860.00 05/07/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691621157
Principal investigator 1 GlaxoSmithKline, LLC. $1,428.30 04/29/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669957305
Principal investigator 1 Merck Sharp & Dohme Corporation $9,355.13 04/15/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691312293
Principal investigator 1 SANOFI PASTEUR INC. $15,550.00 04/09/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618233
Principal investigator 1 SANOFI PASTEUR INC. $8,000.00 04/09/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691619351
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 04/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363753
Principal investigator 1 Merck Sharp & Dohme Corporation $148.50 04/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372079
Principal investigator 1 Merck Sharp & Dohme Corporation $17.60 04/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372083
Principal investigator 1 Merck Sharp & Dohme Corporation $99.00 04/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691372733
Principal investigator 1 SANOFI PASTEUR INC. $2,350.00 04/04/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691620937
Principal investigator 1 SANOFI PASTEUR INC. $200.00 03/28/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691620329
Principal investigator 1 Merck Sharp & Dohme Corporation $105.96 03/27/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691284945
Principal investigator 1 Merck Sharp & Dohme Corporation $1,362.76 03/27/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691285013
Principal investigator 1 Merck Sharp & Dohme Corporation $165.69 03/27/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691285019
Principal investigator 1 Merck Sharp & Dohme Corporation $995.13 03/27/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691539883
Principal investigator 1 Merck Sharp & Dohme Corporation $1,600.00 03/21/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691311797
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 03/19/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691312167
Principal investigator 1 GlaxoSmithKline, LLC. $1,163.70 03/14/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
MENB REC 2ND GEN-023 (V72_57) No dispute reported 06/30/2026 669958413
Principal investigator 1 Merck Sharp & Dohme Corporation $15,292.13 03/13/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691312289
Principal investigator 1 SANOFI PASTEUR INC. $4,980.00 03/12/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691619077
Principal investigator 1 Merck Sharp & Dohme Corporation $1,000.00 03/11/2019 Non-covered Recipient Entity
BIRMINGHAM PEDIATRIC RESEARCH
A Phase II, Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13 in Healthy Infants No dispute reported 06/30/2026 691312251
Principal investigator 1 Merck Sharp & Dohme Corporation $1,522.53 03/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691363759
Principal investigator 1 SANOFI PASTEUR INC. $11,000.00 03/07/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618409
Principal investigator 1 SANOFI PASTEUR INC. $2,155.00 03/07/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691618861
Principal investigator 1 Merck Sharp & Dohme Corporation $52.98 03/06/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283963
Principal investigator 1 Merck Sharp & Dohme Corporation $55.23 03/06/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283971
Principal investigator 1 Merck Sharp & Dohme Corporation $584.04 03/06/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283973
Principal investigator 1 Merck Sharp & Dohme Corporation $331.71 03/06/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691285027
Principal investigator 1 GlaxoSmithKline, LLC. $1,560.60 02/28/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
ROTA-090 No dispute reported 06/30/2026 669973927
Principal investigator 1 Merck Sharp & Dohme Corporation $1,200.00 02/28/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691312165
Principal investigator 1 Merck Sharp & Dohme Corporation $2,900.00 02/26/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691311799
Principal investigator 1 Merck Sharp & Dohme Corporation $12,090.00 02/26/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691312203
Principal investigator 1 Merck Sharp & Dohme Corporation $389.36 02/16/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283949
Principal investigator 1 Merck Sharp & Dohme Corporation $442.28 02/16/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283957
Principal investigator 1 Merck Sharp & Dohme Corporation $73.64 02/16/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691284161
Principal investigator 1 Merck Sharp & Dohme Corporation $35.32 02/16/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691284913
Principal investigator 1 SANOFI PASTEUR INC. $10,000.00 02/14/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691620073
Principal investigator 1 Merck Sharp & Dohme Corporation $124.75 02/13/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691370803
Principal investigator 1 SANOFI PASTEUR INC. $4,550.00 02/05/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691615449
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 01/30/2019 Non-covered Recipient Entity
BIRMINGHAM PEDIATRIC RESEARCH
A Phase II, Double-Blind, Randomized, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar13 in Healthy Infants No dispute reported 06/30/2026 691304183
Principal investigator 1 Merck Sharp & Dohme Corporation $1,800.00 01/29/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691307907
Principal investigator 1 Merck Sharp & Dohme Corporation $9,776.61 01/24/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3-Dose Regimen of V160 Cytomegalovirus CMV Vaccine in Healthy Seronegative Women, 16 to 35 Years of Age No dispute reported 06/30/2026 691304187
Principal investigator 1 AstraZeneca Pharmaceuticals LP $9,746.40 01/23/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics Llc
MEDI8897 RSV mAb-D5290C00003 Phase 2 / 2b Clinical Trial No dispute reported 06/30/2026 684973421
Principal investigator 1 Merck Sharp & Dohme Corporation $389.36 01/17/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283939
Principal investigator 1 Merck Sharp & Dohme Corporation $442.28 01/17/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283953
Principal investigator 1 Merck Sharp & Dohme Corporation $73.64 01/17/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691284025
Principal investigator 1 Merck Sharp & Dohme Corporation $35.32 01/17/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691285031
Principal investigator 1 Merck Sharp & Dohme Corporation $3,684.00 01/17/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase III, Double-Blind, Randomized, Multicenter, Controlled Study to Evaluate the Immunogenicity, Safety, and Tolerability of VARIVAX Passage Extension 34 PE34 Process Administered Concomitantly with M-M-R II No dispute reported 06/30/2026 691307911
Principal investigator 1 SANOFI PASTEUR INC. $13,110.00 01/15/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET42 Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691617251
Principal investigator 1 SANOFI PASTEUR INC. $1,480.00 01/10/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691615389
Principal investigator 1 SANOFI PASTEUR INC. $5,000.00 01/10/2019 Non-covered Recipient Entity
Alabama Clinical Therapeutics LLC
MET41 A Randomized Study to Describe the Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly with Routine Pediatric Vaccines in Healthy Infants and Toddlers No dispute reported 06/30/2026 691617791
Principal investigator 1 Merck Sharp & Dohme Corporation $389.36 01/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283945
Principal investigator 1 Merck Sharp & Dohme Corporation $55.23 01/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691283965
Principal investigator 1 Merck Sharp & Dohme Corporation $35.32 01/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691284909
Principal investigator 1 Merck Sharp & Dohme Corporation $331.71 01/08/2019 Non-covered Recipient Entity
ALABAMA CLINICAL THERAPEUTICS
A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13 with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants PNEU-DIRECTION No dispute reported 06/30/2026 691285023